Free Trial

Onconetix (ONCO) Competitors

Onconetix logo
$3.56 +0.05 (+1.40%)
As of 12:39 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ONCO vs. TLPH, CLDI, LSB, AEON, ARTL, DWTX, JBIO, KPRX, CLRB, and CHRO

Should you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include Talphera (TLPH), Calidi Biotherapeutics (CLDI), LakeShore Biopharma (LSB), AEON Biopharma (AEON), Artelo Biosciences (ARTL), Dogwood Therapeutics (DWTX), Jade Biosciences (JBIO), Kiora Pharmaceuticals (KPRX), Cellectar Biosciences (CLRB), and Chromocell Therapeutics (CHRO). These companies are all part of the "pharmaceutical products" industry.

Onconetix vs. Its Competitors

Talphera (NASDAQ:TLPH) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Talphera has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, Onconetix has a beta of 3.38, meaning that its stock price is 238% more volatile than the S&P 500.

Talphera has higher earnings, but lower revenue than Onconetix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Talphera$650K13.21-$13M-$0.45-0.93
Onconetix$2.52M0.75-$58.69MN/AN/A

Talphera has a net margin of 0.00% compared to Onconetix's net margin of -2,913.71%. Talphera's return on equity of -130.28% beat Onconetix's return on equity.

Company Net Margins Return on Equity Return on Assets
TalpheraN/A -130.28% -59.25%
Onconetix -2,913.71%-514.04%-75.82%

37.7% of Talphera shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 3.2% of Talphera shares are held by company insiders. Comparatively, 3.1% of Onconetix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Talphera currently has a consensus price target of $5.00, suggesting a potential upside of 1,093.32%. Given Talphera's stronger consensus rating and higher possible upside, equities analysts plainly believe Talphera is more favorable than Onconetix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Talphera
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.50
Onconetix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Onconetix had 6 more articles in the media than Talphera. MarketBeat recorded 7 mentions for Onconetix and 1 mentions for Talphera. Talphera's average media sentiment score of 1.89 beat Onconetix's score of 0.32 indicating that Talphera is being referred to more favorably in the media.

Company Overall Sentiment
Talphera Very Positive
Onconetix Neutral

Summary

Talphera beats Onconetix on 12 of the 15 factors compared between the two stocks.

Get Onconetix News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONCO vs. The Competition

MetricOnconetixMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.88M$2.94B$5.54B$9.39B
Dividend YieldN/A2.46%4.25%4.09%
P/E RatioN/A20.7028.2419.90
Price / Sales0.75262.27426.8599.31
Price / CashN/A42.3835.5357.53
Price / Book0.327.838.265.72
Net Income-$58.69M-$55.11M$3.24B$257.71M
7 Day Performance-18.65%2.42%0.62%1.06%
1 Month Performance-13.29%13.14%8.07%11.27%
1 Year Performance-99.30%1.11%27.96%16.81%

Onconetix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONCO
Onconetix
0.2898 of 5 stars
$3.56
+1.4%
N/A-99.3%$1.88M$2.52M0.0012News Coverage
High Trading Volume
TLPH
Talphera
2.3742 of 5 stars
$0.47
+1.9%
$5.00
+959.3%
-52.8%$9.66M$27K-1.0519
CLDI
Calidi Biotherapeutics
0.5638 of 5 stars
$0.30
+24.1%
N/A-66.0%$9.47MN/A0.0038High Trading Volume
LSB
LakeShore Biopharma
0.9589 of 5 stars
$1.20
+21.9%
N/A-76.6%$9.26M$80.82M0.00773Positive News
High Trading Volume
AEON
AEON Biopharma
2.4206 of 5 stars
$0.81
+2.6%
$360.00
+44,235.0%
-99.6%$9.18MN/A4.515
ARTL
Artelo Biosciences
2.6475 of 5 stars
$16.59
+15.9%
$25.00
+50.7%
+90.2%$9.13MN/A-0.935Gap Up
High Trading Volume
DWTX
Dogwood Therapeutics
1.8777 of 5 stars
$4.71
+2.3%
$10.00
+112.5%
N/A$8.99MN/A-0.265Gap Up
JBIO
Jade Biosciences
2.1791 of 5 stars
$10.42
-0.3%
$14.00
+34.4%
N/A$8.76MN/A-0.1720Analyst Forecast
KPRX
Kiora Pharmaceuticals
3.1851 of 5 stars
$2.87
+2.0%
$10.00
+249.0%
-26.6%$8.72MN/A-0.9910News Coverage
CLRB
Cellectar Biosciences
2.2248 of 5 stars
$4.82
+0.3%
$375.00
+7,688.2%
-94.0%$8.72MN/A-0.2210Gap Down
CHRO
Chromocell Therapeutics
N/A$1.34
+6.3%
N/A-88.7%$8.69MN/A-1.084Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:ONCO) was last updated on 7/17/2025 by MarketBeat.com Staff
From Our Partners